HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
Clinical Trial: GVAX Vaccine with Revlimid To Extend Remission
Posted: Jan 24, 2019
Clinical Trial: GVAX Vaccine with Revlimid To Extend Remission image

A new GVAX vaccine is being used in a clinical trial for myeloma patients who have achieved good responses to therapy. The goal of the trial is to extend remissions and potentially deepen responses to a minimal residual disease (MRD) negative state.

This vaccine was tested earlier in Phase I studies by Dr. Ivan Borrello at Johns Hopkins. In the Phase I study, patients who had transplant and then received the vaccine had longer progression free survival than patients who did not receive the vaccine.

A Phase II study is now underway with a treatment arm including the GVAX vaccine, a Prevnar vaccine and Revlimid. The other arm will include Revlimid only.

Patients can join the study if they have received myeloma treatment and had a good response to therapy. Patients can also join if they are over a year out from stem cell transplant (as transplant can modify the immune system), even if they had the transplant a long time ago. The trial requires a patient to also be on Revlimid because it enhances the immune system, although patients can be on low doses of Revlimid. 

The vaccine is given on a monthly basis for 3 months. Then a vaccine booster is given 6 months later, 1 year later and an additional year after that, so approximately 36 months worth of vaccine treatment.  

The vaccine has no major side effects. It is not meant to treat large burdens of myeloma, only to extend remissions. Patients can be in "remission" but need to be MRD positive (or have detectable disease through MRD testing). 

Syed Abbas, MD, MBBS is the lead investigator of the study and joined the Myeloma Crowd at the recent ASH conference to share more in a video.  To learn more about joining this study, watch the video or find this trial on SparkCures. 

GVAX Clinical Trial




The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube